secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001437749-25-032869
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed gets FDA alignment on Phase 3 trial design for neflamapimod in DLB
---------------------------------------------------------------------------

- FDA aligned on primary endpoint (CDR-SB), patient enrichment strategy, and trial design for ~300 DLB patients.
- Enrollment to exclude Alzheimer’s co-pathology via brain imaging, CSF, and plasma ptau181 ≥ 21.0 pg/mL cutoff.
- Phase 3 trial planned to start in H2 2026; 32-week double-blind period followed by 48-week open-label extension.
- No approved therapies for DLB in US or EU; neflamapimod targets cognitive and functional decline.
- Company expects additional global regulatory feedback in coming months; detailed design early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925032869/0001437749-25-032869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925032869/crvo20251104_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer